CLINICAL TRIALS PROFILE FOR ACTOPLUS MET XR
✉ Email this page to a colleague
All Clinical Trials for ACTOPLUS MET XR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01800227 ↗ | Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Under Fasting Conditions | Completed | Torrent Pharmaceuticals Limited | Phase 1 | 1969-12-31 | Objective: subjects to compare the single dose bioavailability of Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets 15 mg/850 mg and Actoplus Met® (pioglitazone hydrochloride and metformin hydrochloride) Tablets 15 mg/850 mg of Takeda Pharmaceuticals America, Inc. USA. Dosing periods of studies were separated by a washout period of 14 days. Study Design: Randomized, Two-Way Crossover, Single-Dose, and Open-Label |
| NCT01800240 ↗ | Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Under Fed Conditions | Completed | Torrent Pharmaceuticals Limited | Phase 1 | 1969-12-31 | Objective: subjects to compare the single dose bioavailability of Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets 15 mg/850 mg and Actoplus Met® (pioglitazone hydrochloride and metformin hydrochloride) Tablets 15 mg/850 mg of Takeda Pharmaceuticals America, Inc. USA. Dosing periods of studies were separated by a washout period of 14 days. Study Design: Randomized, Two-Way Crossover, Single-Dose, and Open-Label |
| NCT02917629 ↗ | ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment | Terminated | National Cancer Institute (NCI) | Phase 2 | 2017-08-14 | This randomized phase IIb trial studies how well ACTOplus met XR works in treating in patients with stage I-IV oral cavity or oropharynx cancer that are undergoing definitive treatment. Chemoprevention is the use of drugs to keep oral cavity or oropharynx cancer from forming or coming back. The use of ACTOplus met XR may slow disease progression in patients with oral cavity or oropharynx cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ACTOPLUS MET XR
Condition Name
| Condition Name for ACTOPLUS MET XR | |
| Intervention | Trials |
| Healthy | 2 |
| Oral Cavity Neoplasm | 1 |
| Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7 | 1 |
| Stage IVB Oropharyngeal Squamous Cell Carcinoma | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for ACTOPLUS MET XR
Trials by Country
Clinical Trial Progress for ACTOPLUS MET XR
Clinical Trial Phase
Clinical Trial Sponsors for ACTOPLUS MET XR
Sponsor Name
